ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0093 • ACR Convergence 2025

    Soluble CD13 engages protease-activated receptor 4 to promote synovial inflammation and angiogenesis in rheumatoid arthritis

    Chenyang Lu1, Megan N Mattichak2, Simin Xu1, William D Brodie3, Neha Khanna2, Hafsa Amin2, Qi Wu2, Phillip Campbell2, David Fox4 and Pei-Suen Tsou5, 1Division of Rheumatology, Department of Internal Medicine, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Guangzhou, China (People's Republic), 2Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, 3Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, Ann Arbor, 4University of Michigan, Dexter, MI, 5University of Michigan, Ann Arbor, MI

    Background/Purpose: Soluble CD13 (sCD13), the soluble form of aminopeptidase N/CD13, exhibits potent chemoattractant, angiogenic, and arthritogenic properties. While we previously identified certain G protein-coupled receptors…
  • Abstract Number: 0073 • ACR Convergence 2025

    HLA-DQA1*01:02 Is Associated With IgG Multi-Reactivity With Citrulline-Containing Type II Collagen Epitopes While HLA-DRB*04:01 Is Associated With More Private Reactivity With Citrulline-Containing IgG Epitopes In Rheumatoid Arthritis

    S. Janna Bashar1, Courtney Myhr1, Adam Titi1, Zihao Zheng1 and Miriam Shelef2, 1University of Wisconsin-Madison, Madison, 2University of Wisconsin-Madison, Madison, WI

    Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) can be promiscuous, with cross-reactive binding to many antigens containing short motifs, or more private with…
  • Abstract Number: 0050 • ACR Convergence 2025

    TL1A expression is upregulated in rheumatic diseases and anti-TL1A antibody reduces disease symptoms and pathological changes in rat collagen-induced arthritis

    Preeyam Patel1, Matthew Siegel2, Emily Lewis3, David Giles3, Justin LaFountaine3, Joshua Friedman3 and Andy Spencer3, 1Spyre Therapeutics, Waltham, 2Spyre Therapeutics, Menlo Park, CA, 3Spyre Therapeutics, Waltham, MA

    Background/Purpose: The development of disease-modifying anti-rheumatic drugs (DMARDs) has reduced disease activity in patients living with rheumatic diseases. Despite this, there is continued unmet need…
  • Abstract Number: 2662 • ACR Convergence 2025

    Target trial emulation of biologic and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis-associated interstitial lung disease

    Gregory McDermott1, Daniel Solomon2, Jeffrey Sparks3 and Rishi Desai3, 1Brigham and Women's Hospital, Brookline, MA, 2Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: RA-ILD is associated with high mortality, but the optimal treatment approach is unclear. While immunosuppressants may treat inflammatory components of ILD, there are concerns…
  • Abstract Number: 2570 • ACR Convergence 2025

    Accelerometer-derived ‘weekend warrior’ physical activity, genetic susceptibility, and incident rheumatoid arthritis: a prospective cohort study

    Zihao Xu1 and Zhixiu Li2, 1Southern University of Science and Technology, ShenZhen, China (People's Republic), 2Southern University of Science and Technology, ShenZhen, Guangdong, China (People's Republic)

    Background/Purpose: Physical activity is associated with a reduced risk of rheumatoid arthritis (RA). However, it is unclear whether the 'weekend warrior' (WW) pattern, characterized by…
  • Abstract Number: 2280 • ACR Convergence 2025

    Changes of B Cell Subsets During Treatment with Abatacept in Patients with Rheumatoid Arthritis

    Athanasios Mavropoulos1, Christos Liaskos2, Ioannis Alexiou3, Christina Katsiari4, Dimitrios Bogdanos5 and Lazaros Sakkas6, 1University of Thessaly, Volos, Greece, 2University of Thessaly, Faculty of Medicine, Larisa, Greece, 3University General Hospital of larissa, Larissa, Greece, 4University General Hospital of Larisa, University of Thessaly Faculty of Medicine, Larisa, Greece, 5Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece, 6Department of Rheumatology, University of Thessaly, Larissa, Greece

    Background/Purpose: Abatacept, an efficacious therapy for rheumatoid arthritis (RA), inhibits the interaction between CD28 on T cells and CD80/CD86 on antigen-presenting cells (APCs). The aim…
  • Abstract Number: 2262 • ACR Convergence 2025

    Assessment of small airway disease in rheumatoid arthritis

    Stéphane HILLIQUIN1, Huy-Thong HUA2, Hà Pham-Ngoc2, Frédérique Aubourg2, Nhât-Nam Lê-Dông2, Sven Günther3, Nicolas ROCHE4, Jérôme AVOUAC5, Yannick Allanore6 and Anh-Tuan Dinh-Xuan2, 1Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France, PARIS, France, 2Unité exploration fonctionnelle respiratoire, Pneumology department, Cochin Hospital, APHP, PARIS, France, 3Unité exploration fonctionnelle respiratoire, Georges-Pompidou Hospital, APHP, PARIS, France, 4Pneumology department, Cochin Hospital, APHP, PARIS, France, 5Rheumatology department, Cochin hospital, Paris, France, 6Université Paris Cité, Paris, France

    Background/Purpose: The risk of interstitial lung disease is well established in Rheumatoid Arthritis (RA). Less is known about the airway involvement which has been estimated…
  • Abstract Number: 2248 • ACR Convergence 2025

    Elevated Anti-PAD Autoantibodies in a Singaporean Chinese Rheumatoid Arthritis (RA) Cohort with Rheumatoid Factor (RF) and Anti-Citrullinated Protein Antibodies (ACPA) Positivity: A Case-control Exploratory Study

    Margaret Ma1, Khai Pang Leong2, ee tzun koh2, Preeti Dhanasekaran3, janique peyper4, bermet abylova4, Anselm Mak3 and Peter Cheung1, 1National University Hospital, Singapore, Singapore, 2Tan Tock Seng Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, Singapore, 4Standard BioTools, Singapore, Singapore

    Background/Purpose: Autoantibody-based biomarkers including ACPA and RF are of established clinical use in rheumatoid arthritis (RA) and are ingrained in international classification criteria. However, other…
  • Abstract Number: 2230 • ACR Convergence 2025

    Racial and Ethnic Disparities in Rheumatoid Arthritis-Associated Interstitial Lung Disease and Their Impact on Antifibrotic Therapy

    Andrea Galecio Chao, Baylor College of Medicine, Houston, TX

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a significant cause of morbidity and mortality among patients with rheumatoid arthritis (RA), often leading to progressive…
  • Abstract Number: 1984 • ACR Convergence 2025

    Improving Lipid Screening Rates in Rheumatic Disease Patients: An Academic Fellowship Quality Improvement Project

    Mahnoor Javed1, Deepak Jagannath2, Lilly Morgan1, Rishi Patel1, Eleonora Avenatti1, Kanika Monga1 and Kenneth Williams1, 1Houston Methodist, Houston, 2Houston Methodist Hospital, Sugar Land, TX

    Background/Purpose: Autoimmune diseases, including rheumatoid arthritis (RA) and spondyloarthritis (SpA)—which encompasses ankylosing spondylitis (AS) and psoriatic arthritis (PsA)—are associated with chronic inflammation and increased cardiovascular…
  • Abstract Number: 1905 • ACR Convergence 2025

    Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States

    Rohan Sharma1, Eric Yen2 and Ram Singh3, 1UCLA, Bakersfield, CA, 2UCLA, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Environmental factors such as smoking, pollutants, diet, and geography as well as sex, race/ethnicity, and genetics have been linked with rheumatoid arthritis (RA) pathogenesis…
  • Abstract Number: 1738 • ACR Convergence 2025

    Coexpression and Infiltration of Endoplasmic Reticulum Stress Proteins Together With CD34+ Fibroblast-like Synoviocytes In Human Inflamed Synovial Membranes

    Zoe Gendebien1, Pauline Salpetier2, Celine Deroyer2, Genevieve Paulissen2, Alexandre Hego2, Gaetan Lefevre2, Christophe Poulet2, Sophie Neuville2, Patrick Durez3, Patrice Hemon4, Nadege Marec5, Elettra Bianchi2, Philippe Delvenne2, Clio ribbens2 and Dominique de Seny2, 1ULiege, Liège, Belgium, 2ULiege, Liege, Belgium, 3Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatologie, Brussels, Brussels Hoofdstedelijk Gewest, Belgium, 4Brest, Brest, Belgium, 5Brest, Brest, France

    Background/Purpose: A strong crosstalk exists between endoplasmic reticulum (ER) stress and synovitis. Several ER chaperone proteins, besides their function in protein folding, can play a…
  • Abstract Number: 1659 • ACR Convergence 2025

    Prevalence and Progression of Multimorbidity in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    James Fagerland1, Yangyuna Yang1, Punyasha Roul2, Tate Johnson1, Scott Matson3, Grant Cannon4, Brian Sauer5, Jeffrey Curtis6, Joshua Baker7, Ted Mikuls1 and Bryant England1, 1University of Nebraska Medical Center, OMAHA, NE, 2UNMC, Omaha, NE, 3University of Kansas, Kansas City, MO, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, 7University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Multimorbidity, the presence of multiple chronic conditions, is common in RA, and the progression of multimorbidity in RA is associated with poor long-term outcomes.…
  • Abstract Number: 1368 • ACR Convergence 2025

    Thrombocytosis Predicts Response to Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis: Data from the Korean KOBIO Registry

    Se Hee Kim1 and kyung-Ann Lee2, 1Kyung Hee University College of Medicine, Seoul, Republic of Korea, 2Soonchunhyang University Hospital Seoul: Soonchunhyang University Hospital, Seoul, Republic of Korea

    Background/Purpose: This study aimed to evaluate the clinical characteristics of thrombocytosis, its relationship with disease activity and joint involvement, and its influence on the effectiveness…
  • Abstract Number: 1350 • ACR Convergence 2025

    Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study

    Daniel Zavada1, Barbora Vala2, Adela Navratilova2, Veronika Losterova2, Lenka Moravcova2, Jiri Vencovsky3, Ladislav Šenolt4, Karel Pavelka5 and Michal Tomcik5, 1Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, 2Institute of Rheumatology, Praha, Czech Republic, 3Institute of Rheumatology, Praha 8, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Rheumatoid arthritis (RA) significantly impacts quality of life in multiple domains. This study aimed to evaluate the impact of initial biologic/targeted synthetic disease-modifying anti-rheumatic…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • …
  • 219
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology